Why the study?
Despite the rise of interventional methods, antiarrhythmic drugs remain the most significant therapy to restore and maintain sinus rhythm in paroxysmal and persistent AF.
Does antiarrhythmic therapy improve prognosis and maintain sinus rhythm in patients with paroxysmal and persistent atrial fibrillation?
Does antiarrhythmic therapy improve prognosis and maintain sinus rhythm in patients with paroxysmal and persistent atrial fibrillation?
Early antiarrhythmic therapy with class 1C and III agents remains a crucial strategy for recovering and maintaining sinus rhythm and improving prognosis in patients with atrial fibrillation.
May support early rhythm control in AF; leaves open need for RCTs on class Ic/III agents.
Despite the emergence and active development of interventional methods for the treatment of arrhythmias, to date, the use of antiarrhythmic drugs to recover and maintain sinus rhythm is the most significant and in demand in patients with paroxysmal and persistent forms of atrial fibrillation (AF). The results of multicenter randomized clinical studies show that early antiarrhythmic therapy to recover and maintain sinus rhythm improves the prognosis for patients with AF. Currently, the most effective and safe drugs to control AF paroxysms and maintain sinus rhythm are class 1C and III agents, according to the Vaughan–Williams classification. The development of new antiarrhythmic drugs brings hope for the emergence of an effective and safe means for the control and prevention of AF, which will significantly improve the quality of life of patients and their prognosis.
No takes yet. Share an insight, caveat, or question.
А. И. Тарзиманова (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: